sars cov 2 s1 protein  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Name:
    SARS CoV 2 2019 nCoV Spike S1 NTD Fc AVI Recombinant Protein
    Description:
    A DNA sequence encoding the SARS CoV 2 2019 nCoV Spike S1 NTD YP 009724390 1 Met1 Ser305 was expressed with a c terminal Fc region of human IgG1 tagged AVI tag at the C terminus
    Catalog Number:
    40591-V41H
    Price:
    None
    Category:
    recombinant protein
    Product Aliases:
    coronavirus spike Protein 2019-nCoV, cov spike Protein 2019-nCoV, ncov RBD Protein 2019-nCoV, ncov s1 Protein 2019-nCoV, ncov s2 Protein 2019-nCoV, ncov spike Protein 2019-nCoV, NCP-CoV RBD Protein 2019-nCoV, NCP-CoV s1 Protein 2019-nCoV, NCP-CoV s2 Protein 2019-nCoV, NCP-CoV Spike Protein 2019-nCoV, novel coronavirus RBD Protein 2019-nCoV, novel coronavirus s1 Protein 2019-nCoV, novel coronavirus s2 Protein 2019-nCoV, novel coronavirus spike Protein 2019-nCoV, RBD Protein 2019-nCoV, S1 Protein 2019-nCoV, S2 Protein 2019-nCoV, Spike RBD Protein 2019-nCoV
    Host:
    HEK293 Cells
    Buy from Supplier


    Structured Review

    Sino Biological sars cov 2 s1 protein
    Identification of 7D2 antibody against <t>SARS-CoV-2</t> S1 protein. The plate coated by 0.2 ug SARS-CoV-2 S1 protein was incubated with 7D2 antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-mouse secondary antibody. The titer of antibody was determined using enzyme-linked immunosorbent assay (ELISA) assay. Significant differences are indicated with an asterisk (unpaired t -test, * p
    A DNA sequence encoding the SARS CoV 2 2019 nCoV Spike S1 NTD YP 009724390 1 Met1 Ser305 was expressed with a c terminal Fc region of human IgG1 tagged AVI tag at the C terminus
    https://www.bioz.com/result/sars cov 2 s1 protein/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 s1 protein - by Bioz Stars, 2021-04
    94/100 stars

    Images

    1) Product Images from "The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice"

    Article Title: The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice

    Journal: bioRxiv

    doi: 10.1101/2020.02.07.939389

    Identification of 7D2 antibody against SARS-CoV-2 S1 protein. The plate coated by 0.2 ug SARS-CoV-2 S1 protein was incubated with 7D2 antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-mouse secondary antibody. The titer of antibody was determined using enzyme-linked immunosorbent assay (ELISA) assay. Significant differences are indicated with an asterisk (unpaired t -test, * p
    Figure Legend Snippet: Identification of 7D2 antibody against SARS-CoV-2 S1 protein. The plate coated by 0.2 ug SARS-CoV-2 S1 protein was incubated with 7D2 antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-mouse secondary antibody. The titer of antibody was determined using enzyme-linked immunosorbent assay (ELISA) assay. Significant differences are indicated with an asterisk (unpaired t -test, * p

    Techniques Used: Incubation, Enzyme-linked Immunosorbent Assay

    2) Product Images from "Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma"

    Article Title: Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma

    Journal: bioRxiv

    doi: 10.1101/2020.12.20.423708

    Genetic basis of a shared, or public, class of IGHV1-24 plasma antibodies targeting the spike NTD. a , IGHV usage of plasma anti-S-ECD or anti-RBD antibodies in all subjects (n=4). b , IGHV1-24 antibodies as a percentage of the circulating IgG plasma antibody repertoire: reactivity to SARS-CoV-2 spike S-ECD or RBD in COVID-19 subjects, or reactivity in healthy subjects to vaccine spike antigens for either respiratory syncytial virus (RSV) or trivalent influenza vaccine hemagglutinin HA1 (TIV). ** p
    Figure Legend Snippet: Genetic basis of a shared, or public, class of IGHV1-24 plasma antibodies targeting the spike NTD. a , IGHV usage of plasma anti-S-ECD or anti-RBD antibodies in all subjects (n=4). b , IGHV1-24 antibodies as a percentage of the circulating IgG plasma antibody repertoire: reactivity to SARS-CoV-2 spike S-ECD or RBD in COVID-19 subjects, or reactivity in healthy subjects to vaccine spike antigens for either respiratory syncytial virus (RSV) or trivalent influenza vaccine hemagglutinin HA1 (TIV). ** p

    Techniques Used:

    Protective spike NTD-targeting antibodies are prevalent in the plasma of convalescent COVID-19 study subjects. a , Temporal dynamics of the anti-S-ECD IgG repertoire at days 12 and 56 post-symptom onset. Titer had increased two-fold by day 56 (data not shown). b , Biolayer interferometry (BLI) sensorgrams to S-ECD ligand of anti-NTD mAbs CM17 and CM25 (subject P2), CM58 (subject P4), and anti-RBD control mAb S309 35 . c , In vitro live virus neutralization. d–f , Prophylactic protection of 12 m.o. BALB/C mice against intranasal challenge with 10 4 PFU of mouse-adapted (MA10) SARS-CoV-2. In vivo prophylactic protection to MA10 challenge; experimental conditions as in Fig 1f,g except challenge dose was 10 5 PFU. *** p
    Figure Legend Snippet: Protective spike NTD-targeting antibodies are prevalent in the plasma of convalescent COVID-19 study subjects. a , Temporal dynamics of the anti-S-ECD IgG repertoire at days 12 and 56 post-symptom onset. Titer had increased two-fold by day 56 (data not shown). b , Biolayer interferometry (BLI) sensorgrams to S-ECD ligand of anti-NTD mAbs CM17 and CM25 (subject P2), CM58 (subject P4), and anti-RBD control mAb S309 35 . c , In vitro live virus neutralization. d–f , Prophylactic protection of 12 m.o. BALB/C mice against intranasal challenge with 10 4 PFU of mouse-adapted (MA10) SARS-CoV-2. In vivo prophylactic protection to MA10 challenge; experimental conditions as in Fig 1f,g except challenge dose was 10 5 PFU. *** p

    Techniques Used: In Vitro, Neutralization, Mouse Assay, In Vivo

    Ig-seq plasma IgG lineage profiles of study subjects at early and late convalescent time points. On the left, the first time point Ig-seq profile (days 11-19) for each subject (subject P3 found in Fig.1 ) shows both the SARS-CoV-2 spike ECD (S-ECD) and RBD abundance for each plasma IgG lineage detected at > 0.5% anti-S-ECD plasma IgG (summed lineage XIC). Similarly, on the right, the second time point data for S-ECD (days 45-56) is shown for each lineage detected at > 0.5% S-ECD plasma IgG abundance (time point 2), alongside early time point S-ECD data for comparison (subject P2 found in Fig.2 ).
    Figure Legend Snippet: Ig-seq plasma IgG lineage profiles of study subjects at early and late convalescent time points. On the left, the first time point Ig-seq profile (days 11-19) for each subject (subject P3 found in Fig.1 ) shows both the SARS-CoV-2 spike ECD (S-ECD) and RBD abundance for each plasma IgG lineage detected at > 0.5% anti-S-ECD plasma IgG (summed lineage XIC). Similarly, on the right, the second time point data for S-ECD (days 45-56) is shown for each lineage detected at > 0.5% S-ECD plasma IgG abundance (time point 2), alongside early time point S-ECD data for comparison (subject P2 found in Fig.2 ).

    Techniques Used:

    Independent live virus neutralization titers of recombinant plasma IgG mAbs CM17, CM25, and CM32. In vitro live virus neutralization curves for CM17, CM25, and CM32 repeated in second independent laboratory demonstrate similar levels of inhibition (as compared to data in Fig.1e and 2c) of live SARS-CoV-2 virus infection of monolayered Vero E6 cells. The percent of infected Vero E6 cells in each sample dilution was normalized relative to the virus-only (no plasma) negative control sample.
    Figure Legend Snippet: Independent live virus neutralization titers of recombinant plasma IgG mAbs CM17, CM25, and CM32. In vitro live virus neutralization curves for CM17, CM25, and CM32 repeated in second independent laboratory demonstrate similar levels of inhibition (as compared to data in Fig.1e and 2c) of live SARS-CoV-2 virus infection of monolayered Vero E6 cells. The percent of infected Vero E6 cells in each sample dilution was normalized relative to the virus-only (no plasma) negative control sample.

    Techniques Used: Neutralization, Recombinant, In Vitro, Inhibition, Infection, Negative Control

    A single spike NTD-targeting IgG antibody in plasma can confer protection without a need for RBD-directed activity. a , Polyclonal IgG plasma antibodies were affinity purified using stabilized spike S-2P S-ECD 2 or RBD, and binding specificity was mapped using purified S subdomains; anti-RBD (green); anti-S2 (blue); anti-NTD (red). b ,The majority of the plasma anti-S-ECD response is directed to non-RBD epitopes: Binding (1:150 plasma dilution) to S-ECD alone, or in the presence of 50 µg/mL (∼1.7 µM) RBD, or S-ΔRBD deletion mutant. c , Quantitative determination of plasma anti-RBD and non-RBD antibody abundance in early convalescence. Abundance normalized to the entire anti-S-ECD plasma IgG repertoire. d , Composition, binding specificity and relative abundance of antibodies in early convalescent plasma (subject P3). e , Authentic virus neutralization of the four topmost abundant plasma IgGs (CM29, CM30, CM31, CM32) from plasma lineages Lin.1, Lin.2, Lin.3, Lin.4 in 1d that account for > 90% of the plasma anti-S-ECD repertoire. f , g Prophylactic protection of 12 m.o. BALB/C mice against lethal challenge with 10 4 PFU mouse-adapted (MA10) SARS-CoV-2 using 200µg/mouse of non-RBD mAbs CM29, CM30, and CM31. Antibody cocktail (200 µg/mouse) consisted of 2:1:1 ratio of CM29, CM30, CM31, reflecting their relative plasma abundance ( 1d ). ** p
    Figure Legend Snippet: A single spike NTD-targeting IgG antibody in plasma can confer protection without a need for RBD-directed activity. a , Polyclonal IgG plasma antibodies were affinity purified using stabilized spike S-2P S-ECD 2 or RBD, and binding specificity was mapped using purified S subdomains; anti-RBD (green); anti-S2 (blue); anti-NTD (red). b ,The majority of the plasma anti-S-ECD response is directed to non-RBD epitopes: Binding (1:150 plasma dilution) to S-ECD alone, or in the presence of 50 µg/mL (∼1.7 µM) RBD, or S-ΔRBD deletion mutant. c , Quantitative determination of plasma anti-RBD and non-RBD antibody abundance in early convalescence. Abundance normalized to the entire anti-S-ECD plasma IgG repertoire. d , Composition, binding specificity and relative abundance of antibodies in early convalescent plasma (subject P3). e , Authentic virus neutralization of the four topmost abundant plasma IgGs (CM29, CM30, CM31, CM32) from plasma lineages Lin.1, Lin.2, Lin.3, Lin.4 in 1d that account for > 90% of the plasma anti-S-ECD repertoire. f , g Prophylactic protection of 12 m.o. BALB/C mice against lethal challenge with 10 4 PFU mouse-adapted (MA10) SARS-CoV-2 using 200µg/mouse of non-RBD mAbs CM29, CM30, and CM31. Antibody cocktail (200 µg/mouse) consisted of 2:1:1 ratio of CM29, CM30, CM31, reflecting their relative plasma abundance ( 1d ). ** p

    Techniques Used: Activity Assay, Affinity Purification, Binding Assay, Purification, Mutagenesis, Neutralization, Mouse Assay

    Live virus neutralization titers of four COVID+ study subjects’ plasma at each collection time point. Serial dilutions of plasma were tested in duplicate (SD error bars) for inhibition of live SARS-CoV-2 virus infection of in vitro monolayered Vero E6 cells. The percent of infected Vero E6 cells in each sample dilution was normalized relative to the virus-only (no plasma) negative control sample.
    Figure Legend Snippet: Live virus neutralization titers of four COVID+ study subjects’ plasma at each collection time point. Serial dilutions of plasma were tested in duplicate (SD error bars) for inhibition of live SARS-CoV-2 virus infection of in vitro monolayered Vero E6 cells. The percent of infected Vero E6 cells in each sample dilution was normalized relative to the virus-only (no plasma) negative control sample.

    Techniques Used: Neutralization, Inhibition, Infection, In Vitro, Negative Control

    3) Product Images from "The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice"

    Article Title: The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice

    Journal: bioRxiv

    doi: 10.1101/2020.02.07.939389

    Identification of 7D2 antibody against SARS-CoV-2 S1 protein. The plate coated by 0.2 ug SARS-CoV-2 S1 protein was incubated with 7D2 antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-mouse secondary antibody. The titer of antibody was determined using enzyme-linked immunosorbent assay (ELISA) assay. Significant differences are indicated with an asterisk (unpaired t -test, * p
    Figure Legend Snippet: Identification of 7D2 antibody against SARS-CoV-2 S1 protein. The plate coated by 0.2 ug SARS-CoV-2 S1 protein was incubated with 7D2 antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-mouse secondary antibody. The titer of antibody was determined using enzyme-linked immunosorbent assay (ELISA) assay. Significant differences are indicated with an asterisk (unpaired t -test, * p

    Techniques Used: Incubation, Enzyme-linked Immunosorbent Assay

    4) Product Images from "The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice"

    Article Title: The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice

    Journal: bioRxiv

    doi: 10.1101/2020.02.07.939389

    Identification of 7D2 antibody against SARS-CoV-2 S1 protein. The plate coated by 0.2 ug SARS-CoV-2 S1 protein was incubated with 7D2 antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-mouse secondary antibody. The titer of antibody was determined using enzyme-linked immunosorbent assay (ELISA) assay. Significant differences are indicated with an asterisk (unpaired t -test, * p
    Figure Legend Snippet: Identification of 7D2 antibody against SARS-CoV-2 S1 protein. The plate coated by 0.2 ug SARS-CoV-2 S1 protein was incubated with 7D2 antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-mouse secondary antibody. The titer of antibody was determined using enzyme-linked immunosorbent assay (ELISA) assay. Significant differences are indicated with an asterisk (unpaired t -test, * p

    Techniques Used: Incubation, Enzyme-linked Immunosorbent Assay

    5) Product Images from "The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice"

    Article Title: The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice

    Journal: bioRxiv

    doi: 10.1101/2020.02.07.939389

    Identification of 7D2 antibody against SARS-CoV-2 S1 protein. The plate coated by 0.2 ug SARS-CoV-2 S1 protein was incubated with 7D2 antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-mouse secondary antibody. The titer of antibody was determined using enzyme-linked immunosorbent assay (ELISA) assay. Significant differences are indicated with an asterisk (unpaired t -test, * p
    Figure Legend Snippet: Identification of 7D2 antibody against SARS-CoV-2 S1 protein. The plate coated by 0.2 ug SARS-CoV-2 S1 protein was incubated with 7D2 antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-mouse secondary antibody. The titer of antibody was determined using enzyme-linked immunosorbent assay (ELISA) assay. Significant differences are indicated with an asterisk (unpaired t -test, * p

    Techniques Used: Incubation, Enzyme-linked Immunosorbent Assay

    Related Articles

    Recombinant:

    Article Title: Subunit Nanovaccine with Potent Cellular and Mucosal Immunity for COVID-19
    Article Snippet: CpG ODN1826 was from InvivoGen (San Diego, CA). .. Recombinant SARS-CoV-2 spike protein (S1) was purchased from Sino Biological (Beijing, China). .. Antimouse PerCP-eFluor 710-CD3, antimouse FITC-CD4, antimouse APC-CD8α, antimouse PE-IFN-γ, antimouse PE/Cy7-TNF-α, and the Zombie Violet Fixable Viability Kit were purchased from Biolegend (San Diego, CA).

    Purification:

    Article Title: The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice
    Article Snippet: The reaction was developed by TMB substrate and the optical densities at 450 nm were determined (Metertech960 enzyme marker with 450 nm wavelength). .. Laboratory preparation of the antibody of SARS-CoV-2 Spike-1 (S1) proteinMice were immunized with purified SARS-CoV-2 S1 protein (Sino biological) and splenocytes of hyper immunized mice were fused with myeloma cells. .. Positive clones were selected by ELISA using SARS-CoV-2 S1 protein ( ).

    Article Title: The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.
    Article Snippet: The reaction was developed by TMB substrate and the optical densities at 450 nm were determined (Metertech960 enzyme marker with 450 nm wavelength). .. Laboratory preparation of the antibody of SARS-CoV-2 spike-1 (S1) protein Mice were immunized with purified SARS-CoV-2 S1 protein (Sino biological) and splenocytes of hyper immunized mice were fused with myeloma cells. .. Positive clones were selected by ELISA using SARS-CoV-2 S1 protein (Extended Data Figure 5).

    Mouse Assay:

    Article Title: The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice
    Article Snippet: The reaction was developed by TMB substrate and the optical densities at 450 nm were determined (Metertech960 enzyme marker with 450 nm wavelength). .. Laboratory preparation of the antibody of SARS-CoV-2 Spike-1 (S1) proteinMice were immunized with purified SARS-CoV-2 S1 protein (Sino biological) and splenocytes of hyper immunized mice were fused with myeloma cells. .. Positive clones were selected by ELISA using SARS-CoV-2 S1 protein ( ).

    Article Title: The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.
    Article Snippet: The reaction was developed by TMB substrate and the optical densities at 450 nm were determined (Metertech960 enzyme marker with 450 nm wavelength). .. Laboratory preparation of the antibody of SARS-CoV-2 spike-1 (S1) protein Mice were immunized with purified SARS-CoV-2 S1 protein (Sino biological) and splenocytes of hyper immunized mice were fused with myeloma cells. .. Positive clones were selected by ELISA using SARS-CoV-2 S1 protein (Extended Data Figure 5).

    Produced:

    Article Title: Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma
    Article Snippet: Costar high binding 96-well assay plates (Corning) were coated with antigens (4 µg ml-1 ) in PBS. .. Antigens included in-house produced SARS-COV-2 spike ECD (S-ECD), SARS-COV-2 spike RBD, as well as commercially obtained SARS-COV-2 spike NTD (Sino Biological). .. Antigen-reactive mAbs were detected with goat anti-human IgG (Fab)-horseradish peroxidase (Sigma-Aldrich) conjugate in 1:5000 PBS.

    Clone Assay:

    Article Title: The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice
    Article Snippet: Laboratory preparation of the antibody of SARS-CoV-2 Spike-1 (S1) proteinMice were immunized with purified SARS-CoV-2 S1 protein (Sino biological) and splenocytes of hyper immunized mice were fused with myeloma cells. .. Positive clones were selected by ELISA using SARS-CoV-2 S1 protein ( ). .. The cell supernatant of 7D2 clone, binding to SARS-CoV-2 S1 protein, was collected for immunofluorescence analysis.

    Enzyme-linked Immunosorbent Assay:

    Article Title: The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice
    Article Snippet: Laboratory preparation of the antibody of SARS-CoV-2 Spike-1 (S1) proteinMice were immunized with purified SARS-CoV-2 S1 protein (Sino biological) and splenocytes of hyper immunized mice were fused with myeloma cells. .. Positive clones were selected by ELISA using SARS-CoV-2 S1 protein ( ). .. The cell supernatant of 7D2 clone, binding to SARS-CoV-2 S1 protein, was collected for immunofluorescence analysis.

    Binding Assay:

    Article Title: The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice
    Article Snippet: Positive clones were selected by ELISA using SARS-CoV-2 S1 protein ( ). .. The cell supernatant of 7D2 clone, binding to SARS-CoV-2 S1 protein, was collected for immunofluorescence analysis. ..

    Immunofluorescence:

    Article Title: The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice
    Article Snippet: Positive clones were selected by ELISA using SARS-CoV-2 S1 protein ( ). .. The cell supernatant of 7D2 clone, binding to SARS-CoV-2 S1 protein, was collected for immunofluorescence analysis. ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Sino Biological sars cov 2 s1 protein
    Identification of 7D2 antibody against <t>SARS-CoV-2</t> S1 protein. The plate coated by 0.2 ug SARS-CoV-2 S1 protein was incubated with 7D2 antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-mouse secondary antibody. The titer of antibody was determined using enzyme-linked immunosorbent assay (ELISA) assay. Significant differences are indicated with an asterisk (unpaired t -test, * p
    Sars Cov 2 S1 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 s1 protein/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 s1 protein - by Bioz Stars, 2021-04
    94/100 stars
      Buy from Supplier

    Image Search Results


    Identification of 7D2 antibody against SARS-CoV-2 S1 protein. The plate coated by 0.2 ug SARS-CoV-2 S1 protein was incubated with 7D2 antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-mouse secondary antibody. The titer of antibody was determined using enzyme-linked immunosorbent assay (ELISA) assay. Significant differences are indicated with an asterisk (unpaired t -test, * p

    Journal: bioRxiv

    Article Title: The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice

    doi: 10.1101/2020.02.07.939389

    Figure Lengend Snippet: Identification of 7D2 antibody against SARS-CoV-2 S1 protein. The plate coated by 0.2 ug SARS-CoV-2 S1 protein was incubated with 7D2 antibody as primary antibody (1:200) and detected using HRP-conjugated goat anti-mouse secondary antibody. The titer of antibody was determined using enzyme-linked immunosorbent assay (ELISA) assay. Significant differences are indicated with an asterisk (unpaired t -test, * p

    Article Snippet: Positive clones were selected by ELISA using SARS-CoV-2 S1 protein ( ).

    Techniques: Incubation, Enzyme-linked Immunosorbent Assay

    Genetic basis of a shared, or public, class of IGHV1-24 plasma antibodies targeting the spike NTD. a , IGHV usage of plasma anti-S-ECD or anti-RBD antibodies in all subjects (n=4). b , IGHV1-24 antibodies as a percentage of the circulating IgG plasma antibody repertoire: reactivity to SARS-CoV-2 spike S-ECD or RBD in COVID-19 subjects, or reactivity in healthy subjects to vaccine spike antigens for either respiratory syncytial virus (RSV) or trivalent influenza vaccine hemagglutinin HA1 (TIV). ** p

    Journal: bioRxiv

    Article Title: Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma

    doi: 10.1101/2020.12.20.423708

    Figure Lengend Snippet: Genetic basis of a shared, or public, class of IGHV1-24 plasma antibodies targeting the spike NTD. a , IGHV usage of plasma anti-S-ECD or anti-RBD antibodies in all subjects (n=4). b , IGHV1-24 antibodies as a percentage of the circulating IgG plasma antibody repertoire: reactivity to SARS-CoV-2 spike S-ECD or RBD in COVID-19 subjects, or reactivity in healthy subjects to vaccine spike antigens for either respiratory syncytial virus (RSV) or trivalent influenza vaccine hemagglutinin HA1 (TIV). ** p

    Article Snippet: Antigens included in-house produced SARS-COV-2 spike ECD (S-ECD), SARS-COV-2 spike RBD, as well as commercially obtained SARS-COV-2 spike NTD (Sino Biological).

    Techniques:

    Protective spike NTD-targeting antibodies are prevalent in the plasma of convalescent COVID-19 study subjects. a , Temporal dynamics of the anti-S-ECD IgG repertoire at days 12 and 56 post-symptom onset. Titer had increased two-fold by day 56 (data not shown). b , Biolayer interferometry (BLI) sensorgrams to S-ECD ligand of anti-NTD mAbs CM17 and CM25 (subject P2), CM58 (subject P4), and anti-RBD control mAb S309 35 . c , In vitro live virus neutralization. d–f , Prophylactic protection of 12 m.o. BALB/C mice against intranasal challenge with 10 4 PFU of mouse-adapted (MA10) SARS-CoV-2. In vivo prophylactic protection to MA10 challenge; experimental conditions as in Fig 1f,g except challenge dose was 10 5 PFU. *** p

    Journal: bioRxiv

    Article Title: Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma

    doi: 10.1101/2020.12.20.423708

    Figure Lengend Snippet: Protective spike NTD-targeting antibodies are prevalent in the plasma of convalescent COVID-19 study subjects. a , Temporal dynamics of the anti-S-ECD IgG repertoire at days 12 and 56 post-symptom onset. Titer had increased two-fold by day 56 (data not shown). b , Biolayer interferometry (BLI) sensorgrams to S-ECD ligand of anti-NTD mAbs CM17 and CM25 (subject P2), CM58 (subject P4), and anti-RBD control mAb S309 35 . c , In vitro live virus neutralization. d–f , Prophylactic protection of 12 m.o. BALB/C mice against intranasal challenge with 10 4 PFU of mouse-adapted (MA10) SARS-CoV-2. In vivo prophylactic protection to MA10 challenge; experimental conditions as in Fig 1f,g except challenge dose was 10 5 PFU. *** p

    Article Snippet: Antigens included in-house produced SARS-COV-2 spike ECD (S-ECD), SARS-COV-2 spike RBD, as well as commercially obtained SARS-COV-2 spike NTD (Sino Biological).

    Techniques: In Vitro, Neutralization, Mouse Assay, In Vivo

    Ig-seq plasma IgG lineage profiles of study subjects at early and late convalescent time points. On the left, the first time point Ig-seq profile (days 11-19) for each subject (subject P3 found in Fig.1 ) shows both the SARS-CoV-2 spike ECD (S-ECD) and RBD abundance for each plasma IgG lineage detected at > 0.5% anti-S-ECD plasma IgG (summed lineage XIC). Similarly, on the right, the second time point data for S-ECD (days 45-56) is shown for each lineage detected at > 0.5% S-ECD plasma IgG abundance (time point 2), alongside early time point S-ECD data for comparison (subject P2 found in Fig.2 ).

    Journal: bioRxiv

    Article Title: Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma

    doi: 10.1101/2020.12.20.423708

    Figure Lengend Snippet: Ig-seq plasma IgG lineage profiles of study subjects at early and late convalescent time points. On the left, the first time point Ig-seq profile (days 11-19) for each subject (subject P3 found in Fig.1 ) shows both the SARS-CoV-2 spike ECD (S-ECD) and RBD abundance for each plasma IgG lineage detected at > 0.5% anti-S-ECD plasma IgG (summed lineage XIC). Similarly, on the right, the second time point data for S-ECD (days 45-56) is shown for each lineage detected at > 0.5% S-ECD plasma IgG abundance (time point 2), alongside early time point S-ECD data for comparison (subject P2 found in Fig.2 ).

    Article Snippet: Antigens included in-house produced SARS-COV-2 spike ECD (S-ECD), SARS-COV-2 spike RBD, as well as commercially obtained SARS-COV-2 spike NTD (Sino Biological).

    Techniques:

    Independent live virus neutralization titers of recombinant plasma IgG mAbs CM17, CM25, and CM32. In vitro live virus neutralization curves for CM17, CM25, and CM32 repeated in second independent laboratory demonstrate similar levels of inhibition (as compared to data in Fig.1e and 2c) of live SARS-CoV-2 virus infection of monolayered Vero E6 cells. The percent of infected Vero E6 cells in each sample dilution was normalized relative to the virus-only (no plasma) negative control sample.

    Journal: bioRxiv

    Article Title: Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma

    doi: 10.1101/2020.12.20.423708

    Figure Lengend Snippet: Independent live virus neutralization titers of recombinant plasma IgG mAbs CM17, CM25, and CM32. In vitro live virus neutralization curves for CM17, CM25, and CM32 repeated in second independent laboratory demonstrate similar levels of inhibition (as compared to data in Fig.1e and 2c) of live SARS-CoV-2 virus infection of monolayered Vero E6 cells. The percent of infected Vero E6 cells in each sample dilution was normalized relative to the virus-only (no plasma) negative control sample.

    Article Snippet: Antigens included in-house produced SARS-COV-2 spike ECD (S-ECD), SARS-COV-2 spike RBD, as well as commercially obtained SARS-COV-2 spike NTD (Sino Biological).

    Techniques: Neutralization, Recombinant, In Vitro, Inhibition, Infection, Negative Control

    A single spike NTD-targeting IgG antibody in plasma can confer protection without a need for RBD-directed activity. a , Polyclonal IgG plasma antibodies were affinity purified using stabilized spike S-2P S-ECD 2 or RBD, and binding specificity was mapped using purified S subdomains; anti-RBD (green); anti-S2 (blue); anti-NTD (red). b ,The majority of the plasma anti-S-ECD response is directed to non-RBD epitopes: Binding (1:150 plasma dilution) to S-ECD alone, or in the presence of 50 µg/mL (∼1.7 µM) RBD, or S-ΔRBD deletion mutant. c , Quantitative determination of plasma anti-RBD and non-RBD antibody abundance in early convalescence. Abundance normalized to the entire anti-S-ECD plasma IgG repertoire. d , Composition, binding specificity and relative abundance of antibodies in early convalescent plasma (subject P3). e , Authentic virus neutralization of the four topmost abundant plasma IgGs (CM29, CM30, CM31, CM32) from plasma lineages Lin.1, Lin.2, Lin.3, Lin.4 in 1d that account for > 90% of the plasma anti-S-ECD repertoire. f , g Prophylactic protection of 12 m.o. BALB/C mice against lethal challenge with 10 4 PFU mouse-adapted (MA10) SARS-CoV-2 using 200µg/mouse of non-RBD mAbs CM29, CM30, and CM31. Antibody cocktail (200 µg/mouse) consisted of 2:1:1 ratio of CM29, CM30, CM31, reflecting their relative plasma abundance ( 1d ). ** p

    Journal: bioRxiv

    Article Title: Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma

    doi: 10.1101/2020.12.20.423708

    Figure Lengend Snippet: A single spike NTD-targeting IgG antibody in plasma can confer protection without a need for RBD-directed activity. a , Polyclonal IgG plasma antibodies were affinity purified using stabilized spike S-2P S-ECD 2 or RBD, and binding specificity was mapped using purified S subdomains; anti-RBD (green); anti-S2 (blue); anti-NTD (red). b ,The majority of the plasma anti-S-ECD response is directed to non-RBD epitopes: Binding (1:150 plasma dilution) to S-ECD alone, or in the presence of 50 µg/mL (∼1.7 µM) RBD, or S-ΔRBD deletion mutant. c , Quantitative determination of plasma anti-RBD and non-RBD antibody abundance in early convalescence. Abundance normalized to the entire anti-S-ECD plasma IgG repertoire. d , Composition, binding specificity and relative abundance of antibodies in early convalescent plasma (subject P3). e , Authentic virus neutralization of the four topmost abundant plasma IgGs (CM29, CM30, CM31, CM32) from plasma lineages Lin.1, Lin.2, Lin.3, Lin.4 in 1d that account for > 90% of the plasma anti-S-ECD repertoire. f , g Prophylactic protection of 12 m.o. BALB/C mice against lethal challenge with 10 4 PFU mouse-adapted (MA10) SARS-CoV-2 using 200µg/mouse of non-RBD mAbs CM29, CM30, and CM31. Antibody cocktail (200 µg/mouse) consisted of 2:1:1 ratio of CM29, CM30, CM31, reflecting their relative plasma abundance ( 1d ). ** p

    Article Snippet: Antigens included in-house produced SARS-COV-2 spike ECD (S-ECD), SARS-COV-2 spike RBD, as well as commercially obtained SARS-COV-2 spike NTD (Sino Biological).

    Techniques: Activity Assay, Affinity Purification, Binding Assay, Purification, Mutagenesis, Neutralization, Mouse Assay

    Live virus neutralization titers of four COVID+ study subjects’ plasma at each collection time point. Serial dilutions of plasma were tested in duplicate (SD error bars) for inhibition of live SARS-CoV-2 virus infection of in vitro monolayered Vero E6 cells. The percent of infected Vero E6 cells in each sample dilution was normalized relative to the virus-only (no plasma) negative control sample.

    Journal: bioRxiv

    Article Title: Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma

    doi: 10.1101/2020.12.20.423708

    Figure Lengend Snippet: Live virus neutralization titers of four COVID+ study subjects’ plasma at each collection time point. Serial dilutions of plasma were tested in duplicate (SD error bars) for inhibition of live SARS-CoV-2 virus infection of in vitro monolayered Vero E6 cells. The percent of infected Vero E6 cells in each sample dilution was normalized relative to the virus-only (no plasma) negative control sample.

    Article Snippet: Antigens included in-house produced SARS-COV-2 spike ECD (S-ECD), SARS-COV-2 spike RBD, as well as commercially obtained SARS-COV-2 spike NTD (Sino Biological).

    Techniques: Neutralization, Inhibition, Infection, In Vitro, Negative Control